Survival paradox persists between stage IIB/C and IIIA colon cancer, even after adjusting for chemotherapy and lymph node retrieval. Optimal treatment for IIIA yields significantly better 5-year survival rates compared to IIB/C. Stage remains an independent predictor of overall survival, with significant differences in survival outcomes between different sub-stages. The TNM system should consider revising to address this discrepancy.
Journal Article by Chu QD, Li T (…) Wu XC et 6 al. in Surg Endosc
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.